ALK and non-small cell lung carcinoma: A randomized phase III study reported that, in the subgroup of ALK-rearranged NSCLC, patients treated with crizotinib showed higher response rate and longer progression-free survival (PFS) compared with those treated with the standard second-line chemotherapies (docetaxel or pemetrexed) [14].